Login:
 
Savill P. Direct oral anticoagulants reduce all-cause mortality in AF. Practitioner June 2019;263(1827): 5

Direct oral anticoagulants reduce all-cause mortality in AF

24 Jun 2019Registered users

Direct oral anticoagulant (DOAC) therapy in patients with non-valvular atrial fibrillation (AF) was associated with a significantly lower risk of death compared with no anticoagulation, in a retrospective cohort study, published in Heart. In this cohort of newly diagnosed patients with moderate- to high-risk non-valvular AF treated in routine clinical practice, DOAC therapy was associated with a 31% reduction in all-cause mortality.

Registered usersThis article can only be accessed if you are a registered user of thepractitioner.co.uk or a subscriber to The Practitioner.

To buy this article (£25+tax) copy the article citation above and click Buy article